Stock Comparison

ABBV vs RMD

AbbVie Inc vs Resmed Inc

The Verdict

Dead heat. Both scored 0.1/10.

ABBV

AbbVie Inc

0.1

out of 10

Distressed

RMD

Resmed Inc

0.1

out of 10

Distressed

Head-to-Head

$381.1B

Market Cap

$28.4B

104.8

P/E Ratio

18.7

5.8%

Profit Margin

27.4%

95.6%

Return on Equity

24.4%

20.2

Debt-to-Equity

0.1

Moderate

Overall Risk

Moderate

0.1

DVR Score

0.1

The Deep Dive

ABBV0.1/10

AbbVie (ABBV) remains a well-established mega-cap pharmaceutical company, demonstrating stable, incremental growth driven by its robust immunology portfolio, notably Skyrizi and Rinvoq. Q1 2026 results showed modest revenue and adjusted EPS growth, with slightly raised full-year guidance. While financially healthy and a strong dividend payer, its immense market capitalization ($381.10B) and the ma...

Full ABBV Analysis

RMD0.1/10

ResMed Inc. (RMD) continues to demonstrate robust performance as a global leader in sleep apnea and respiratory care. Its Q3 FY2026 results showed healthy 10.8% YoY revenue growth, EPS beat ($2.86 vs $2.79 consensus), and gross margin expansion to 62.8%. These are strong indicators of a well-managed, profitable company in an established healthcare sector. However, this analysis specifically target...

Full RMD Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.